Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Demelza Emmerton & Ahmed Abdelhafiz. (2021) Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people. Hospital Practice 49:3, pages 164-175.
Read now
Read now
Luigi Della Corte, Virginia Foreste, Fabio Barra, Claudio Gustavino, Franco Alessandri, Maria Grazia Centurioni, Simone Ferrero, Giuseppe Bifulco & Pierluigi Giampaolino. (2020) Current and experimental drug therapy for the treatment of polycystic ovarian syndrome. Expert Opinion on Investigational Drugs 29:8, pages 819-830.
Read now
Read now
Rosemarie Lajara. (2019) Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgraduate Medicine 131:8, pages 555-565.
Read now
Read now
Mattia Galli, Domenico D’Amario, Carmelo Sofia, Marcello Vaccarella, Filippo Crea & Nadia Aspromonte. (2018) Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opinion on Drug Metabolism & Toxicology 14:12, pages 1273-1285.
Read now
Read now
Emanuel Raschi, Arianna Mazzotti, Elisabetta Poluzzi, Fabrizio De Ponti & Giulio Marchesini. (2018) Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 19:17, pages 1903-1914.
Read now
Read now
Articles from other publishers (18)
Teodor Salmen, Liviu-Ionut Serbanoiu, Ioana-Cristina Bica, Cristian Serafinceanu, Emir Muzurović, Andrej Janez, Stefan Busnatu, Maciej Banach, Ali Abbas Rizvi, Manfredi Rizzo & Anca Pantea Stoian. (2023) A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 24:11, pages 9760.
Crossref
Crossref
Pierre Gourdy, Patrice Darmon, François Dievart, Jean-Michel Halimi & Bruno Guerci. (2023) Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovascular Diabetology 22:1.
Crossref
Crossref
玉娇 姜. (2022) Research Progress on the Protective Effect of SGLT2 Inhibitor on Kidney. Advances in Clinical Medicine 12:05, pages 3926-3930.
Crossref
Crossref
Qing Li, Xiaoyan Deng, Neng Jiang, Liuwei Meng, Junhao Xing, Weizhe Jiang & Yanjun Xu. (2021) Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. European Journal of Medicinal Chemistry 225, pages 113765.
Crossref
Crossref
Katherine Frieling, Scott V. Monte, David Jacobs & Nicole Paolini Albanese. (2021) Weight loss differences seen between glucagon-like peptide–1 receptor agonists and sodium–glucose cotransporter–2 inhibitors for treatment of type 2 diabetes. Journal of the American Pharmacists Association 61:6, pages 772-777.
Crossref
Crossref
Ronald M. Goldenberg, Vineeta Ahooja, Kristin K. Clemens, Jeremy D. Gilbert, Megha Poddar & Subodh Verma. (2021) Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. Canadian Journal of Diabetes 45:3, pages 291-302.
Crossref
Crossref
Ahmed H. Abdelhafiz & Alan J. Sinclair. (2020) Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy. Journal of Diabetes and its Complications 34:9, pages 107639.
Crossref
Crossref
Giulia Di Dalmazi, Sara Coluzzi, Maria P.A. Baldassarre, Sofia Elena Sorbo, Stefania Dell’Aquila, Fabrizio Febo, Federica Ginestra, Giusi Graziano, Maria C. Rossi, Agostino Consoli & Gloria Formoso. (2020) Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting. Clinical Therapeutics 42:9, pages 1738-1749.e1.
Crossref
Crossref
Michael Fralick, Seoyoung C Kim, Sebastian Schneeweiss, Brendan M Everett, Robert J Glynn & Elisabetta Patorno. (2020) Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ, pages m2812.
Crossref
Crossref
John E. Anderson. (2020) Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. Diabetes Spectrum 33:2, pages 165-174.
Crossref
Crossref
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, Miwa Kawanaka, Hideki Fujii, Masato Yoneda, Kento Imajo, Hirokazu Takahashi, Yuichiro Eguchi, Masafumi Ono, Yuichi Nozaki, Hideyuki Hyogo, Masahiro Koseki, Yuichi Yoshida, Takumi Kawaguchi, Yoshihiro Kamada, Takeshi Okanoue & Atsushi Nakajima. (2020) Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences 21:6, pages 1907.
Crossref
Crossref
Héctor Eloy Tamez-Pérez, Enrique Delgadillo-Esteban & Alejandra Lorena Tamez-Peña. (2020) Underutilization of insulin and better metabolic control. A NOVA clinic experience. Revista da Associação Médica Brasileira 66:3, pages 334-337.
Crossref
Crossref
Francesco Giorgino, Irene Caruso, Julia Moellmann & Michael Lehrke. (2020) Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 104, pages 154045.
Crossref
Crossref
Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Ning-I Yang, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang & Edward Chia-Cheng Lai. (2019) Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Hye Jung Park, Heejae Han, Eun-Yi Oh, Sung Ryeol Kim, Kyung Hee Park, Jae-Hyun Lee & Jung-Won Park. (2019) Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model. Scientific Reports 9:1.
Crossref
Crossref
Yan Li, Ling Li, Yong De Peng, Guang Yao Song, Shan Dong Ye, Li Ying Du, Jia Ning Hou & Qiu He Ji. (2019) Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2). Diabetes Therapy 10:4, pages 1435-1452.
Crossref
Crossref
A. Bonaventura, S. Carbone, D. L. Dixon, A. Abbate & F. Montecucco. (2019)
Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on
SGLT
‐2 inhibitors and
GLP
‐1 receptor agonists
. Journal of Internal Medicine 286:1, pages 16-31.
Crossref
Crossref
Georgios A. Christou, Niki Katsiki, John Blundell, Gema Fruhbeck & Dimitrios N. Kiortsis. (2019) Semaglutide as a promising antiobesity drug. Obesity Reviews 20:6, pages 805-815.
Crossref
Crossref